Telix Launches Imaging Agent Illuccix
Illuccix is approved to detect prostate cancer when using PET scan. It is available through Cardinal Health, PharmaLogic, and United Pharmacy Partners.
Telix has launched it prostate cancer imaging agent, Illuccix (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection.
Illuccix is available from 117 Cardinal Health and PharmaLogic pharmacies. In addition, United Pharmacy Partners has been added as a third pharmacy network partner on a select basis.
The FDA approved Illuccix in December 2021 as radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen positive lesions in patients with prostate cancer with:
- suspected metastasis who are candidates for initial definitive therapy;
- suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
“The approval of Illuccix will give patients considerably improved access to PSMA-PET imaging, an advanced diagnostic tool that was recently included in the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer,” Oliver Sartor, M.D. medical director at Tulane Cancer Center, said at the time of the approval. “With patient doses able to be prepared on-site or via commercial radiopharmacy networks, either via generator or cyclotron, Illuccix delivers flexible patient scheduling and on-demand access throughout the day.”
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
